Is there a role for retreatment with immunotherapy in patients progressing after initial treatment with immunotherapy for metastatic non small cell lung cancer and who achieve complete or partial response at two years?

The data regarding discontinuation of immunotherapy at 2 years comes mainly from melanoma studies with pembrolizumab. The data in melanoma is strong that therapy can be discontinued, and in these patients the 24-month disease free survival after discontinuation was nearly 90%. The data for NSCLC is ...

Yes. If this was an elective, planned stop at two years (and not due to progression or toxicity), there is a role for retreatment. The two-year course of pembrolizumab was somewhat arbitrary and not based on strong evidence. Many of the initial studies of MK-3475 (pembrolizumab) and other PD(L)1 inh...